Advanced non-squamous NSCLC:Tiragolumab+atezo did not improve OS
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Related Articles
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups,…
AI Use in Surgeries for Prostate Cancer May Help Standardize Outcomes
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
Breast cancer survivors with BRCA mutations at greater risk for second primary malignancies
Breast cancer survivors who harbor BRCA gene mutation are at elevated risk for second primary cancers, according to study results.These individuals likely would benefit from…
Cold air makes oxygen toxic for worms
A new study from a postbaccalaureate researcher in Mark Roth’s lab at Fred Hutch Cancer Center, Cameron Suraci, shows that microscopic worms exposed to frigid…
2024 Year in Review
Leonidas Platanias, MD, PhD Director, Lurie Cancer Center In 2024, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University continued to advance our understanding…
A Pragmatist’s View on Biomarker-Driven Decisions in Oncology: Episode 2
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Clinical Insights | JCO Oncology Practice
This clinical insights article is derived from recommendations in Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. This document is based on…
Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL
Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.
American Society of Hematology Announces 2025 Scholar Award Recipients – Hematology.org
American Society of Hematology Announces 2025 Scholar Award Recipients
Retreatment With R-CHOP-Like Therapy Yields Durable Remission in Late-Relapse DLBCL
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in…
